The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

This systematic review and network meta-analysis of 601 eligible trials found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1 receptor agonists were ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...